# Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder

> **NCT02839200** · PHASE2 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 360 (actual)

## Conditions studied

- Insomnia Disorder

## Interventions

- **DRUG:** ACT-541468 5 mg
- **DRUG:** ACT-541468 10 mg
- **DRUG:** ACT-541468 25 mg
- **DRUG:** Zolpidem
- **DRUG:** Placebo 1
- **DRUG:** Placebo 2

## Key facts

- **NCT ID:** NCT02839200
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-04
- **Primary completion:** 2017-04-12
- **Final completion:** 2017-06-20
- **Target enrollment:** 360 (ACTUAL)
- **Last updated:** 2020-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02839200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02839200, "Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02839200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*